1. Introduction
===============

Breast cancer (BC) is one of the frequent malignancies and is the leading cause of cancer-related mortality in women, with an estimated 268,670 new cases and 41,400 deaths in the United States in 2018.^\[[@R1]\]^ Surgery remains the gold standard for treatment of patients with BC. However, the prognosis remains unsatisfactory due to the recurrence and metastasis, with 5-year and 10-year survival rate of approximately 80% and 60%.^\[[@R2]\]^ Also, there are several patients who are not reluctant to undergo surgical resection in clinic.^\[[@R3]\]^ Therefore, it is essential to stratify the patients preoperatively and then the surgery is only strongly recommended for the patients with excellent prognostic outcomes.

Current studies have reported tumor size, pathologic tumor, node, metastasis (TNM) staging, Ki67 expression, receptor status (estrogen receptor, ER; progesterone receptor, PR; human epidermal growth factor receptor 2, HER2) and molecular subtypes (lumina-type, HER2-positive, and triple-negative) are significantly associated with the prognosis of patients with BC.^\[[@R4]--[@R6]\]^ However, most of these factors are usually obtained under the requirement of core biopsies and with the aid of molecular technique, which is invasive and costly. Their prognostic accuracy is also reported to be unsatisfactory, with the example of the different TNM stage or molecular subtypes having the same prognoses.^\[[@R7]\]^ Thus, more easily available and efficient preoperative prognostic parameters are desirable to guide individualized treatment.

Emerging evidence has demonstrated inflammation exerts important roles in the development and progression of cancer.^\[[@R8],[@R9]\]^ Moreover, blood-based tests for inflammatory factors are easy to perform, less expensive, and readily available. Thus, a serial of inflammatory immune cells (i.e., neutrophil, lymphocyte, white cells) and cytokines (i.e., C-reactive protein, interleukin 6 and tumor necrosis factor alpha) have been suggested as underlying prognostic biomarkers.^\[[@R10]\]^ Of them, the ratio of absolute neutrophil count to absolute lymphocyte count (NLR) is the most commonly investigated indicator for assessment of the inflammatory status in patients with cancer.^\[[@R11],[@R12]\]^ A higher preoperative NLR is reported to be associated with poor survival in patients with BC.^\[[@R13],[@R14]\]^ However, some studies failed to find the correlation between the preoperative NLR and the overall survival (OS) of patients with BC.^\[[@R15],[@R16]\]^ Furthermore, in some clinical trials, only white cell and neutrophil counts are routinely detected and thus the derived NLR (dNLR) \[defined as absolute neutrophil count divided by the derived lymphocyte count (absolute leukocyte count--neutrophil count)\] was also used for NLR alternative. Also, it remains controversial on the prognostic role of dNLR for BC.^\[[@R17],[@R18]\]^ Hereby, the goal of this study was to further evaluate the prognostic potential of preoperative NLR and dNLR for BC patients using a meta-analysis.

2. Materials and methods
========================

2.1. Search strategy
--------------------

A systematic literature search was carried out independently by 2 investigators in PubMed and Cochrane Library databases for screening studies published to September 2018 that assessed the relationship between preoperative NLR and the prognosis of patients with BC. The search keywords included: "NLR" (or "neutrophil to lymphocyte ratio" or "neutrophil lymphocyte ratio" or "neutrophil-to-lymphocyte") AND "breast cancer" AND "surgery" (or "resection"). In addition, the reference lists of all identified publications as well as pertinent reviews and meta-analyses were also manually screened to further obtain potentially eligible literatures. This analysis was performed in accordance to the Guidelines of the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA).^\[[@R19]\]^ Ethics approval was not applicable as this is a meta-analytic study.

2.2. Selection criteria
-----------------------

Two investigators independently selected the relevant articles according to the inclusion criteria: BC was confirmed by pathological examination; NLR was measured by serum-based method preoperatively or at initial diagnosis (which was not influenced by neoadjuvant); prognostic outcomes \[like OS, disease-free survival (DFS), recurrence-free survival (RFS) and disease specific survival (DSS)\] were investigated; and hazard ratio (HR) with a 95% confidence interval (CI) could be directly obtained or indirectly estimated. Exclusion criteria were: duplicated literatures; abstracts, meta-analysis, reviews, letters, editorials, case reports, comments or non-clinical studies (animal experiments); HR and 95%CI were unavailable; NLR was measured after neoadjuvant or postoperatively; and literature written in language other than English.

2.3. Data extraction
--------------------

Two reviewers independently extracted the following data: first author' name, publication year, country of origin, sample size, study design, characteristics of patients (including age, stage, duration of follow-up), treatment strategies, treatment outcome, cut-off value of NLR and dNLR, HR with 95%CI for survival and related statistical methods. HR and 95%CI were extracted preferentially from multivariable analyses, otherwise from univariate analysis results.

Quality assessment was conducted using the Scottish Intercollegiate Guidelines Network (SIGN) checklists.^\[[@R20]\]^ Good quality was presented as double plus (2++) which denoted cohort studies had very low risk of confounding, bias, or chance and a high probability that the relationship is causal; acceptable quality was presented as single plus (2+) which denoted cohort studies had a low risk of confounding, bias, or chance and a moderate probability that the relationship is causal; low quality was presented as a minus (2−) indicated cohort studies had high risk of confounding, bias, or chance and a significant risk that the relationship is not causal. Any disagreement in the data extraction and quality assessment was resolved by consensus.

2.4. Statistical analysis
-------------------------

Extracted data were pooled using the STATA software (version 13.0; STATA Corporation, College Station, TX). Statistical heterogeneity among the studies was assessed with Cochrane\'s *Q* (Chi-squared) and *I*^2^ statistic.^\[[@R21]\]^ A random-effects model was used for heterogeneous studies (*Q* test *P* value \< .10 and *I*^2^ \> 50%); otherwise, the fixed-effects model was applied in the absence of heterogeneity. Publication bias was assessed with Egger\'s linear regression test and funnel plots.^\[[@R22]\]^ The influence of publication bias on the overall effect was tested by the "trim and fill" method.^\[[@R23]\]^ Sensitivity analysis was performed based on the leave-one-out approach. In addition, subgroup analyses were also performed for ethnicity, publication year, sample size, stage, follow-up time, cut-off, statistical methods, and adjuvant therapy. *P* \< .05 was considered to be statistically significant.

3. Results
==========

3.1. Study characteristics
--------------------------

Twenty-one studies^\[[@R13],[@R16]--[@R18],[@R24]--[@R39]\]^ comprising a total of 10,599 patients were included according to the search strategy and the inclusion/exclusion criteria (Fig. [1](#F1){ref-type="fig"}). Of them, 20 studies^\[[@R13],[@R16],[@R18],[@R24]--[@R39]\]^ including 9837 participants were included for NLR and 3 studies,^\[[@R4],[@R17],[@R31]\]^ including 2950 participants for dNLR. All studies collected data retrospectively. Twelve studies included only patients with early stage breast cancer (stage I--III), while 9 included both early and metastatic disease. Patients in most of the studies did not receive neoadjuvant (15/21, 71.4%), but a large proportion of them (90.5%) underwent adjuvant therapy (including chemotherapy, radiotherapy, and hormone therapy). The other characteristics of the included studies are shown in Table [1](#T1){ref-type="table"}. Four studies were rated as SIGN level 2++, 11 were 2+ and 6 were 2−, suggesting most of our selected articles were of high quality.
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Characteristics of included studies.
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3.2. Association between NLR and BC survival
--------------------------------------------

There were 12 studies to investigate the prognostic significance of preoperative NLR for OS in BC patients. A significant heterogeneity was present between the studies (*I*^2^ = 60.6%, *P = *.003) and thus a random-effects model was chosen to pool the study results. Pooled results showed that elevated NLR was significantly associated with poorer OS (HR = 2.45, 95% CI: 1.69--3.54, *P \< *.001) (Fig. [2](#F2){ref-type="fig"}A) in BC patients undergoing surgery.

![Forest plots of the correlation of neutrophil to lymphocyte ratio with survival. (A) Overall survival; (B) disease-free survival; (C) recurrence-free survival.](medi-97-e13340-g003){#F2}

Fifteen studies assessed the prognostic significance of preoperative NLR for DFS in BC patients. There was evidence of a significant heterogeneity between the studies (I^2^ = 83.9%, *P \< *.001) and thus a random-effects model was used. Pooled results showed that elevated NLR was significantly associated with poorer DFS (HR = 1.54, 95% CI: 1.28--1.87, *P \< *.001) (Fig. [2](#F2){ref-type="fig"}B) in BC patients undergoing surgery.

Two studies analyzed the preoperative NLR for predicting the RFS of BC patients. A fixed effect was adopted to pool the study results because of *I*^2^ = 0% and *P = *.84. The pooled estimates analysis predicted that RFS was significantly lower in BC patients with an elevated NLR (HR = 4.05, 95% CI: 1.94--8.47, *P \< *.001) (Fig. [2](#F2){ref-type="fig"}C).

There were 3 studies to investigate the prognostic significance of preoperative NLR for DSS in BC patients. A random-effects model were applied to pool the study results because a significant heterogeneity was detected between the studies (*I*^2^ = 76.3%, *P = *.015). The pooled results that no significant association between preoperative NLR and DSS for patients with BC (HR = 2.17, 95% CI: 0.97--4.82, *P = *.058).

3.3. Association between dNLR and BC survival
---------------------------------------------

Two studies analyzed the association between preoperative dNLR and OS of BC patients. A fixed-effects was adopted to pool the study results because of *I*^2^ = 0% and *P = *.599. The pooled estimates analysis indicated that high-preoperative dNLR was also significantly associated with worse OS (HR = 1.75, 95% CI: 1.39--2.19, *P \< *.001) (Fig. [3](#F3){ref-type="fig"}A).
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There were 3 studies to investigate the prognostic value of preoperative dNLR for DFS in BC patients. A random-effects model were applied to pool the study results because an obvious heterogeneity was present between the studies (*I*^2^ = 81.43%, *P = *.004). The pooled results that high preoperative dNLR was significantly associated with DFS (HR = 1.62, 95% CI: 1.09--2.41, *P = *.017) (Fig. [3](#F3){ref-type="fig"}B).

3.4. Publication bias
---------------------

The publication bias was present in NLR for DFS (*P = *.007), but not in NLR for OS (*P = *.436) and DSS (*P = *.144) as well as dNLR for DFS (*P = *.363). Subsequently, a trim-and-fill method was performed to explore the influence of publication bias on the effect estimate. The filled meta-analysis indicated no significant association was present between preoperative NLR and DFS (HR = 1.19; 95%CI: 0.98--1.44, *P = *.081), indicating the prognostic value of preoperative NLR for DFS needed further confirmation (Fig. [4](#F4){ref-type="fig"}).
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3.5. Sensitivity analyses
-------------------------

Sensitivity analysis was conducted by assessing the potential impact of individual studies on the pooled HR. The results showed that pooled HR was not significantly altered when each study was successively deleted (Fig. [5](#F5){ref-type="fig"}).
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3.6. Subgroup analysis
----------------------

The subgroup analyses according to ethnicity, publication year, sample size, stage, follow-up time, cut-off, statistical methods, and adjuvant therapy were performed for NLR. The results showed that significant associations between preoperative elevated NLR and poor OS were not changed by the stratification of ethnicity (eastern or western), cutoff of NLR, pathological stage, neoadjuvant and adjuvant therapy, while the associations between preoperative elevated NLR and poor DFS were only significant in Eastern countries with follow-up duration longer than 50 months (Table [2](#T2){ref-type="table"}). Few studies only performed the univariate analyses and heterogeneity may be present, leading to no significant associations between preoperative elevated NLR and poor OS/DFS with this analysis (Table [2](#T2){ref-type="table"}).
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Subgroup analysis.
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4. Discussion
=============

Although there were studies to use the meta-analysis approach to determine the prognostic role of NLR in BC, all of them focused on the pretreatment, but not paid attention on the surgery effects independently.^\[[@R11],[@R12],[@R40],[@R41]\]^ Also, all the included articles in these meta-analyses^\[[@R11],[@R12],[@R40],[@R41]\]^ were published before April 2016 and the evidence extensively accumulated therewith has not been enrolled. Our present study, for the first time, used the meta-analysis to specifically assess the prognostic value of preoperative NLR and prognosis in BC patients undergoing surgery with the literature updated to September 2018. The sample size was further expanded and more believable conclusion may be achieved. Our study identified 20 studies and the initial pooled meta-analysis results indicated that patients with higher preoperative NLR had shorter OS, DFS, and RFS outcomes in patients with BC. However, the significant association of NLR with DFS was vanished after correction of publication bias using the trim-and-fill method. Subgroup analyses predicted the nationality of patients, follow-up duration and statistical methods might be the major sources of heterogeneity to influence the prognostic importance of elevated NLR on DFS outcomes with only significant associations in Eastern populations, follow-up \> 50 months and multivariate analyses. Our finding seemed to be different from the previous meta-analyses that found a high NLR appeared to be a negative prognostic marker in western populations,^\[[@R11],[@R12]\]^ further demonstrating the necessity of our study.

In addition, dNLR has been used for NLR alternative in several clinical trials. There was also evidence to show an independent significant association between high dNLR and poor OS as well as DFS outcomes in patients with BC^\[[@R17]\]^ and other cancers^\[[@R42],[@R43]\]^. However, the meta-analysis for integrative assessment of the prognostic value of dNLR with controversial literatures^\[[@R17],[@R18]\]^ had not been reported previously. In this study, we, for the first time, included 3 articles of BC and proved high-preoperative dNLR was also significantly associated with worse OS and DFS in patients with BC.

An elevated NLR/dNLR indicated the neutrophil-dependent inflammatory reaction was increased, but lymphocyte-mediated antitumor immune response was lower. There have evidence to demonstrate tumor associated neutrophils support metastatic initiation of BC.^\[[@R44],[@R45]\]^ Neutrophil-derived leukotrienes aided the colonization of distant tissues by selectively expanding the subpool of cancer cells that retain high tumorigenic potential. Inhibition of the leukotriene-generating enzyme arachidonate 5-lipoxygenase may abrogate pro-metastatic activity of neutrophils and reduce lung metastasis.^\[[@R45]\]^ Anticancer drugs (i.e., 5-fluorouracil) mediated aggravation of BC metastasis to lung was also attributed to increased intrapulmonary neutrophil numbers and expression of neutrophilic chemokines (C-X-C motif chemokine ligand 1, Cxcl1 and Cxcl2) in tumor cells. The administration of a neutrophil-depleting antibody or a C-X-C motif chemokine receptor 2 (Cxcr2) antagonist, SB225002, significantly attenuated 5-fluorouracil-mediated enhanced lung metastasis.^\[[@R46]\]^ Donati et al^\[[@R47]\]^ also reported neutrophils may promote adhesiveness, invasiveness, and migration of BC cells by secreting cytokine interleukin-16, while instillation of an interleukin-16 neutralizing antibody reversed the effects of neutrophils. Even, Coffelt et al^\[[@R48]\]^ found tumor-induced neutrophils may promote the establishment of pulmonary and lymph node metastases by suppressing cytotoxic T lymphocytes. BC patients with metastases are more prone to have shorter survival time. In line with these studies, we also found the HR of NLR for poor OS was higher in studies with mixed stage (having metastatic cases) than the early stage.

There are several limitations in this meta-analysis. Firstly, all of enrolled studies were retrospective, which may lead to some biases. Secondly, only 3 studies were included to evaluate the prognostic significance of dNLR for survival, which may lead to the overestimation or underestimation of its value. Thirdly, most of studies included neo-adjuvant and/or adjuvant treatment protocols and the survival outcomes may be influenced. Fourthly, the cut-off value for the NLR differed in each study although it was both significant according to our subgroup analysis. This may influence their clinical application.

In conclusion, this meta-analysis demonstrates preoperative NLR/dNLR may be effective predictive biomarkers for prognosis in patients with BC. Detection of NLR/dNLR may be helpful to identify the patients who benefit from the surgery.
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